Caroline Kozek
Adult Health · Hackensack, NJNPI 1912623265
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,920 of the $7,454 with a category attached, or 66.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 22.5%. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $38.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Blueprint Medicines Corporation$920
- Incyte Corporation$819
- Taiho Oncology, Inc.$548
- Daiichi Sankyo Inc.$534
- Takeda Pharmaceuticals U.S.A., Inc.$531
- plus $2K from 26 others
What the payments were for
- Consulting fees$1,40319%
- Speaking & faculty fees$85711%
- Food & beverage$4,92066%
- Education$2744%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $1,674 |
| Blueprint Medicines Corporation | 19 | $920 |
| Incyte Corporation | 15 | $819 |
| Taiho Oncology, Inc. | 20 | $548 |
| Daiichi Sankyo Inc. | 26 | $534 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $531 |
| Pharmaessentia USA Corporation | 12 | $495 |
| E.r. Squibb & Sons, L.L.C. | 3 | $364 |
| AbbVie | 6 | $326 |
| GSK | 5 | $198 |
| Geron Corporation | 12 | $190 |
| Johnson & Johnson | 2 | $115 |
| Astellas Pharma US Inc | 5 | $95 |
| CTI Biopharma Corp. | 6 | $85 |
| Sobi, Inc | 4 | $71 |
| Sanofi | 4 | $69 |
| Autolus Inc | 4 | $66 |
| Adaptive Biotechnologies Corporation | 3 | $53 |
| Pharmacosmos Therapeutics Inc. | 1 | $41 |
| Merck | 2 | $36 |
| AstraZeneca | 2 | $32 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Genmab U.S., Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| Syndax Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,454 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 55 | $1,055,412 |
| AyvakitAvapritinib | 12 | $691,040 |
| PromactaEltrombopag Olamine | 13 | $432,303 |
| InqoviDecitabine/Cedazuridine | 15 | $120,583 |
| VenclextaVenetoclax | 34 | $106,887 |
| Posaconazole | 23 | $20,600 |
| Imatinib Mesylate | 15 | $8,088 |
| Ciprofloxacin Hcl | 87 | $1,899 |
| Acyclovir | 91 | $1,523 |
| Fluconazole | 49 | $1,338 |
| Hydroxyurea | 26 | $438 |
| ValacyclovirValacyclovir Hcl | 16 | $389 |
| Ondansetron Hcl | 37 | $282 |
| Potassium Chloride | 16 | $210 |
| Tramadol Hcl | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $819 | $1,055,41255 claims |
| Blueprint Medicines CorporationAyvakit | $920 | $691,04012 claims |
| NovartisPromacta | $1,674 | $432,30313 claims |
| Taiho Oncology, Inc.Inqovi | $548 | $120,58315 claims |
| AbbVieVenclexta | $326 | $106,88734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Hackensack
- June HalperHackensack$358K
- Phyllis McKiernanHackensack$72K
- Samantha DepadovaHackensack$34K
- Pamela SutherlandHackensack$22K
- Rosemarie WellmanHackensack$9K
- Derrick RodriguezHackensack$8K
- Susan KumkaHackensack$8K
- Rey PellaHackensack$6K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.